Analyst Ratings For NASDAQ:ABEO – Abeona Therapeutics (NASDAQ:ABEO)
Today, Cantor Fitzgerald reiterated its Buy rating on NASDAQ:ABEO – Abeona Therapeutics (NASDAQ:ABEO) with a price target of $36.00.
Some recent analyst ratings include
- 5/16/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 1/24/2018-Royal Bank of Canada Reiterated Rating of Buy.
- 11/22/2017-Jefferies Group Reiterated Rating of Buy.
- 10/10/2017-Citigroup initiated coverage with a Buy rating.
Recent Insider Trading Activity For NASDAQ:ABEO – Abeona Therapeutics (NASDAQ:ABEO)
NASDAQ:ABEO – Abeona Therapeutics (NASDAQ:ABEO) has insider ownership of 6.70% and institutional ownership of 62.04%.
- On 9/20/2016 Todd Wider, Director, bought 5,000 with an average share price of $5.48 per share and the total transaction amounting to $27,400.00.
- On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00.
- On 1/26/2015 Mark J Ahn, Director, bought 25,000 with an average share price of $4.00 per share and the total transaction amounting to $100,000.00.
- On 12/24/2014 Steven H Rouhandeh, Director, bought 250,000 with an average share price of $4.00 per share and the total transaction amounting to $1,000,000.00.
Recent Trading Activity for NASDAQ:ABEO – Abeona Therapeutics (NASDAQ:ABEO)
Shares of NASDAQ:ABEO – Abeona Therapeutics closed the previous trading session at 20.60 up +0.10 0.49% with 20.25 shares trading hands.
